Meeting
2014 ASCO Annual Meeting
Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
Authors
John Howard Sampson
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, NC
John Howard Sampson , Gordana Vlahovic , Annick Desjardins , Henry S. Friedman , Joachim M. Baehring , David Hafler , Linda Rollin , Vlad Coric , Susan N. Perez , David A. Reardon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02017717
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS2101)
DOI
10.1200/jco.2014.32.15_suppl.tps2101
Abstract #
TPS2101
Poster Bd #
66A
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.
First Author: John H. Sampson
Poster
2022 ASCO Annual Meeting
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
First Author: Julia Katharina Schwarze
Poster
2018 ASCO Annual Meeting
NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma.
First Author: Andrew E. Sloan
Poster
2022 ASCO Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.
First Author: Wolfgang Wick